Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCODONE HYDROCHLORIDE AND IBUPROFEN vs HYDROCODONE BITARTRATE AND ACETAMINOPHEN
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Oxycodone is a full mu-opioid receptor agonist, leading to analgesia, euphoria, and sedation. Ibuprofen inhibits cyclooxygenase (COX)-1 and COX-2, reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and providing analgesic and antipyretic effects.
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate,Off-label: Treatment of chronic pain when other options fail
Management of moderate to moderately severe pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate.
One tablet containing oxycodone hydrochloride 5 mg and ibuprofen 400 mg orally every 6 hours as needed for pain; maximum 4 tablets per day.
Oral: 1-2 tablets (5-10 mg hydrocodone/325-650 mg acetaminophen) every 4-6 hours as needed for pain; maximum daily doses: hydrocodone 40 mg, acetaminophen 3000 mg.
Oxycodone: 3-5 hours; Ibuprofen: 1.8-2.5 hours. Clinical context: Oxycodone's half-life allows dosing every 4-6 hours; Ibuprofen's shorter half-life supports frequent dosing for sustained anti-inflammatory effect.
Hydrocodone: 3.8-7.4 hours (terminal), prolonged in hepatic impairment. Acetaminophen: 1.5-2.5 hours (terminal).
GFR 30-89 m L/min: No adjustment recommended. GFR 15-29 m L/min: Use with caution; consider reducing dose or extending interval; avoid use in severe renal impairment (GFR <30 m L/min) due to risk of ibuprofen accumulation and nephrotoxicity. GFR <15 m L/min: Not recommended.
e GFR 30-89 m L/min: No adjustment. e GFR <30 m L/min: Avoid use or reduce dose and frequency. Hemodialysis: Not recommended.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of just one dose, especially by children, can be fatal; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity due to ibuprofen.
First trimester: Limited data; opioid use associated with neural tube defects and congenital heart defects in some studies; ibuprofen associated with increased risk of cardiac defects and gastroschisis. Second trimester: Ibuprofen may cause oligohydramnios and premature closure of fetal ductus arteriosus. Third trimester: Prolonged use may cause neonatal opioid withdrawal syndrome; ibuprofen contraindicated due to risk of premature ductus arteriosus closure, oligohydramnios, and fetal nephrotoxicity.
First trimester: Limited human data; animal studies show no consistent teratogenicity. Second and third trimesters: Chronic use may cause fetal opioid dependence, neonatal withdrawal syndrome, and reduced fetal growth. Acetaminophen component: no known teratogenic risk at therapeutic doses.
Combination product (oxycodone 5 mg/ibuprofen 400 mg) indicated for acute moderate-to-severe pain; limit duration to ≤7 days due to opioid dependence and GI/renal risks; avoid in patients with aspirin/NSAID allergy, asthma, or severe hepatic/renal impairment; monitor for respiratory depression, hypotension, and signs of bleeding; prescribe naloxone for high-risk patients.
Hydrocodone/acetaminophen carries a boxed warning for addiction, abuse, and misuse; respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; and hepatotoxicity (acetaminophen). Avoid in patients with severe respiratory depression, acute or severe bronchial asthma, GI obstruction, or known acetaminophen hypersensitivity. Maximum acetaminophen dose from all sources should not exceed 4 g/day (3 g/day in at-risk patients). Use with caution in elderly, cachectic, or debilitated patients due to increased risk of respiratory depression. CYP3A4 inducers (e.g., rifampin) may reduce hydrocodone efficacy; CYP3A4 inhibitors (e.g., ketoconazole) may increase toxicity. Do not combine with other CNS depressants without dose adjustment. Monitor for signs of opioid-induced constipation; prescribe a bowel regimen. Prescribe immediate-release formulations only for acute pain (generally ≤3 days). Avoid combining with MAOIs or within 14 days of MAOI use.
No interactions on record
No interactions on record
OXYCODONE HYDROCHLORIDE AND IBUPROFEN and HYDROCODONE BITARTRATE AND ACETAMINOPHEN are distinct pharmacological agents. OXYCODONE HYDROCHLORIDE AND IBUPROFEN belongs to the Opioid Agonist class and is primarily used for Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequateOff-label: Treatment of chronic pain when other options fail. HYDROCODONE BITARTRATE AND ACETAMINOPHEN belongs to the Opioid Agonist class and is primarily used for Management of moderate to moderately severe pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate.. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. OXYCODONE HYDROCHLORIDE AND IBUPROFEN carries a safety status of Category D/X, whereas HYDROCODONE BITARTRATE AND ACETAMINOPHEN safety is classified as Category D/X. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Oxycodone is metabolized primarily via CYP3A4 and CYP2D6 to active metabolites (noroxycodone, oxymorphone). Ibuprofen is metabolized via CYP2C9 and CYP2C8 to inactive metabolites.
Hydrocodone: primarily CYP3A4 and CYP2D6 to hydromorphone (active). Acetaminophen: primarily glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation to NAPQI (toxic).
Oxycodone: primarily renal (87%) as metabolites, with ~19% unchanged; Ibuprofen: renal (90%) as metabolites, with ~10% unchanged; small biliary/fecal elimination for both.
Renal excretion of metabolites (hydrocodone: ~60% as conjugates, <12% unchanged; acetaminophen: ~85-90% as glucuronide and sulfate conjugates, <5% unchanged). Biliary/fecal elimination of minor metabolites.
Oxycodone: ~45% bound to albumin; Ibuprofen: >99% bound to albumin.
Hydrocodone: ~20-50% bound to albumin and other proteins. Acetaminophen: 10-25% bound to albumin.
Oxycodone: Vd 2.0-3.0 L/kg (high tissue distribution: CNS, muscle); Ibuprofen: Vd 0.1-0.2 L/kg (limited to plasma and extracellular fluid).
Hydrocodone: 3.3-4.7 L/kg (extensive tissue distribution). Acetaminophen: 0.75-1.0 L/kg (primarily total body water).
Oral: Oxycodone 60-87% (higher with repeated dosing due to saturation of first-pass); Ibuprofen 80-100% (rapidly absorbed).
Oral: Hydrocodone ~70-80% (first-pass metabolism). Acetaminophen ~60-90% (product dependent).
Child-Pugh Class A (mild): No adjustment recommended. Child-Pugh Class B (moderate): Use with caution; reduce starting dose of oxycodone by 50% (e.g., half tablet) and monitor; ibuprofen should be avoided or used at lowest effective dose. Child-Pugh Class C (severe): Contraindicated due to risk of hepatic encephalopathy and bleeding.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce total daily dose by 50% or extend dosing interval. Child-Pugh C: Avoid use.
Not approved in children <18 years of age. For weight-based dosing in adolescents (≥18 years): same as adult based on oxycodone component 0.05-0.15 mg/kg/dose (max 5 mg) and ibuprofen 5-10 mg/kg/dose (max 400 mg) every 6 hours as needed; not to exceed 4 doses per day.
Not recommended for children <18 years due to safety concerns. For postoperative tonsillectomy/adenoidectomy: contraindicated.
Start at lowest effective dose (one-half tablet every 6 hours) due to increased sensitivity to opioids (respiratory depression, constipation) and NSAID-related GI/renal risks; monitor renal function and for cognitive impairment; maximum 4 tablets per day.
Initiate at lowest effective dose (e.g., 2.5 mg hydrocodone/325 mg acetaminophen) and titrate slowly; monitor for CNS depression and constipation. Avoid in renal impairment.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen overdose.
Respiratory depression; addiction potential; interactions with CNS depressants; hepatic impairment; renal toxicity; gastrointestinal bleeding; cardiovascular thrombotic events; adrenal insufficiency; use in elderly; use in pregnancy; breastfeeding.
Respiratory depression, drug dependence, abuse potential, risks with CNS depressants, elderly/debilitated patients, hepatic impairment, renal impairment, severe hypotension, head injury, seizures, use in pregnancy, use in breastfeeding, adrenal insufficiency, anaphylaxis, withdrawal, and driving impairment.
Significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; hypersensitivity to oxycodone, ibuprofen, or any component; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; in the setting of coronary artery bypass graft (CABG) surgery.
Significant respiratory depression, acute or severe bronchial asthma, GI obstruction (including paralytic ileus), hypersensitivity to hydrocodone or acetaminophen, severe hepatic impairment, and known or suspected gastrointestinal obstruction.
Take with food or milk to reduce GI upset. Avoid grapefruit and grapefruit juice (may increase oxycodone levels and risk of adverse effects). Limit alcohol intake due to additive CNS depression and increased GI bleeding risk.
Avoid alcohol consumption due to increased risk of hepatotoxicity and additive CNS depression. Grapefruit juice may inhibit CYP3A4 and potentially increase hydrocodone levels; consider avoiding or limiting intake. No significant food restrictions otherwise; may take with or without food. Maintain adequate hydration to prevent constipation.
Oxycodone excreted in breast milk; M/P ratio approximately 1.1. Ibuprofen excreted in low levels (M/P <0.01). American Academy of Pediatrics considers both compatible with breastfeeding; however, monitor infant for sedation, respiratory depression, and poor feeding due to oxycodone.
Hydrocodone is excreted into human breast milk, with an M/P ratio approximately 2.5. Postpartum use may lead to infant sedation and respiratory depression, especially in CYP2D6 ultra-rapid metabolizers. Acetaminophen is excreted in low levels. Use is generally avoided due to risks; if used, monitor infant for drowsiness and feeding difficulties.
No established dose adjustments for pregnancy; however, increased renal clearance and volume of distribution in pregnancy may require dose increases for adequate analgesia. Avoid supratherapeutic ibuprofen doses; limit to lowest effective dose and shortest duration. Third trimester: avoid ibuprofen entirely.
No dosing adjustment recommended specifically for pregnancy, but pharmacokinetic changes (increased clearance, volume of distribution) may result in lower serum concentrations; however, due to fetal risks, use the lowest effective dose for the shortest duration. Avoid use in third trimester unless necessary; monitor for neonatal withdrawal.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness and respiratory depression.,Do not drive or operate machinery until you know how this medication affects you.,This drug contains both an opioid and an NSAID; risk of addiction, respiratory depression, and GI bleeding.,Do not take with other NSAIDs (e.g., ibuprofen, naproxen) or acetaminophen-containing products without medical advice.,Swallow tablets whole; do not crush, chew, or dissolve (may cause rapid release and overdose).,Common side effects: constipation, nausea, dizziness, drowsiness; increase fluids and fiber to prevent constipation.,Seek emergency help if you experience trouble breathing, chest pain, severe dizziness, black/tarry stools, or signs of allergic reaction.,Keep out of reach of children and dispose of unused medication via drug take-back program.,Inform all healthcare providers that you are taking this medication before any surgery or procedure.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush, chew, or dissolve extended-release tablets; swallow whole.,Avoid alcohol and any products containing acetaminophen (e.g., Tylenol, cold medicines) to prevent liver damage.,Do not drive or operate heavy machinery until you know how this medication affects you.,Store in a secure place away from children and pets; dispose of unused medication via a drug take-back program.,Contact your doctor immediately if you experience shallow breathing, difficulty waking, confusion, or signs of allergic reaction.,Do not stop abruptly; withdrawal symptoms include anxiety, sweating, diarrhea, and muscle aches.,Inform all healthcare providers that you are taking this medication.,Use exactly as directed; misuse can lead to addiction, overdose, or death.